Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.95 Billion KRW | 54.45% |
| 2022 | -30.44 Billion KRW | 25.97% |
| 2021 | 30.77 Billion KRW | -50.25% |
| 2020 | 52.41 Billion KRW | 61.8% |
| 2019 | 11.48 Billion KRW | -25.31% |
| 2018 | 10.21 Billion KRW | 9.96% |
| 2017 | 3.42 Billion KRW | -1.68% |
| 2016 | 9.67 Billion KRW | 98.83% |
| 2015 | 6.05 Billion KRW | -55.64% |
| 2014 | 10.69 Billion KRW | 9.63% |
| 2013 | 9.77 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.7 Billion KRW | 911.92% |
| 2024 Q1 | 287.61 Million KRW | -1643.02% |
| 2023 FY | - KRW | 54.45% |
| 2023 Q3 | 4.45 Billion KRW | -8.95% |
| 2023 Q1 | 2.56 Billion KRW | 0.31% |
| 2023 Q4 | 35.7 Million KRW | -99.2% |
| 2023 Q2 | 4.89 Billion KRW | 90.63% |
| 2022 Q4 | 2.55 Billion KRW | -22.84% |
| 2022 FY | - KRW | 25.97% |
| 2022 Q3 | 3.31 Billion KRW | 161.55% |
| 2022 Q2 | 1.26 Billion KRW | 113.15% |
| 2022 Q1 | 594.92 Million KRW | 40.31% |
| 2021 FY | - KRW | -50.25% |
| 2021 Q4 | 423.99 Million KRW | 200.19% |
| 2021 Q2 | 2.71 Billion KRW | -20.55% |
| 2021 Q1 | 3.42 Billion KRW | 35.87% |
| 2021 Q3 | -423.2 Million KRW | -115.56% |
| 2020 FY | - KRW | 61.8% |
| 2020 Q1 | 2.14 Billion KRW | -38.07% |
| 2020 Q2 | 4.06 Billion KRW | 89.2% |
| 2020 Q3 | 4.27 Billion KRW | 5.17% |
| 2020 Q4 | 2.51 Billion KRW | -41.05% |
| 2019 Q3 | 397.45 Million KRW | -32.57% |
| 2019 Q1 | 1.94 Billion KRW | 17.54% |
| 2019 FY | - KRW | -25.31% |
| 2019 Q4 | 3.46 Billion KRW | 772.78% |
| 2019 Q2 | 589.41 Million KRW | -69.75% |
| 2018 Q2 | 3.09 Billion KRW | -16.81% |
| 2018 FY | - KRW | 9.96% |
| 2018 Q4 | 1.65 Billion KRW | -26.09% |
| 2018 Q3 | 2.24 Billion KRW | -27.45% |
| 2018 Q1 | 3.71 Billion KRW | -22.51% |
| 2017 FY | - KRW | -1.68% |
| 2017 Q1 | 1.95 Billion KRW | -55.24% |
| 2017 Q2 | 2.28 Billion KRW | 16.77% |
| 2017 Q3 | 468.75 Million KRW | -79.46% |
| 2017 Q4 | 4.79 Billion KRW | 923.14% |
| 2016 FY | - KRW | 98.83% |
| 2016 Q4 | 4.36 Billion KRW | 527.61% |
| 2016 Q3 | -1.02 Billion KRW | -170.02% |
| 2016 Q2 | 1.45 Billion KRW | -57.17% |
| 2016 Q1 | 3.4 Billion KRW | 17.08% |
| 2015 Q3 | -1.23 Billion KRW | -189.78% |
| 2015 Q2 | 1.37 Billion KRW | 53.09% |
| 2015 Q1 | 900.98 Million KRW | -83.19% |
| 2015 FY | - KRW | -55.64% |
| 2015 Q4 | 2.9 Billion KRW | 334.83% |
| 2014 Q2 | 1.64 Billion KRW | -20.84% |
| 2014 Q1 | 2.07 Billion KRW | -38.09% |
| 2014 Q3 | 1.47 Billion KRW | -10.02% |
| 2014 Q4 | 5.35 Billion KRW | 262.86% |
| 2014 FY | - KRW | 9.63% |
| 2013 Q4 | 3.34 Billion KRW | 893.27% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q2 | 3.03 Billion KRW | 31.91% |
| 2013 Q3 | 337.15 Million KRW | -88.88% |
| 2013 Q1 | 2.29 Billion KRW | 0.0% |
| 2012 Q3 | -112.67 Million KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 108.099% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 323.8% |
| BINEX Co., Ltd. | 10.87 Billion KRW | -28.34% |
| Bioneer Corporation | 10.04 Billion KRW | -38.931% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 3286.928% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 171.954% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 132.603% |
| Helixmith Co., Ltd | -53 Billion KRW | 126.325% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 80.092% |
| Medy-Tox Inc. | 32.69 Billion KRW | 57.327% |
| Peptron, Inc. | -12.65 Billion KRW | 210.297% |
| Genexine, Inc. | -40.87 Billion KRW | 134.134% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | -69.549% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 119.546% |
| ALTEOGEN Inc. | 440.04 Million KRW | -3070.87% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 86.616% |
| SillaJen, Inc. | -17.35 Billion KRW | 180.41% |
| JETEMA, Co., Ltd. | 11 Billion KRW | -26.757% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 225.308% |
| Genomictree Inc. | -6.33 Billion KRW | 320.365% |
| MedPacto, Inc. | -32.6 Billion KRW | 142.79% |
| D&D Pharmatech | -9.05 Billion KRW | 254.044% |
| EASY BIO,Inc. | 24.32 Billion KRW | 42.634% |
| GI Innovation, Inc. | -51.33 Billion KRW | 127.183% |